Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space ...

Enveda’s pipeline is led by ENV-294, a first-in-class, oral small molecule being developed to treat atopic dermatitis and other inflammatory conditions by combining the advantages of blockbuster drugs ...

He wants to deflate an over $4 Trillion bill for in health care costs and deliver on his vision to restore good health to ...

Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

WASHINGTON — The Biden administration announced last Tuesday it’s reinterpreting federal law to allow Medicare and Medicaid patients access to anti-obesity medications to reduce their weight over the ...

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Ozempic, Wegovy, and other weight-loss drugs could make millions healthier, but access and affordability barriers abound.

State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...